Core Insights - Coldwell Banker Realty's McNair Group, led by Billy McNair, achieved a closed residential sales volume of $215 million in 2024, ranking as the top-performing medium agent team and earning the Society of Excellence designation, which is awarded to the top 1 percent of agents nationwide [1][6][7] Group Performance - The McNair Group consists of six members and has consistently ranked among the top-performing teams, appearing on Real Trends Top 1000 and America's Best rankings [3] - Notable sales in 2024 included properties at 138 Almendral Avenue for $19.5 million, 1170 May Brown Avenue for $13.75 million, and 2 Marymont Avenue for $15.8 million, which sold for $1 million over the asking price [2] Leadership and Expertise - Billy McNair has over 515 units sold and $2 billion in career sales, bringing extensive expertise to the real estate market [4] - McNair's qualifications include being a licensed attorney and holding an MBA, which enhances his ability to navigate real estate transactions and analyze market conditions [4] Company Overview - Coldwell Banker Realty operates over 600 offices in the U.S. and represents more than 52,000 independent real estate agents [8]

Over 230 Italian and U.S. executives, Italian government leaders, and investors attended the eighth edition of "Italy On the Move" Seven life sciences executives provided business insights during "Navigating Transatlantic Partnerships in Life Sciences" panel discussion and five Italian startups pitched their unique breakthroughs and investment opportunities Director General for the Promotion of Italy Mauro Battocchi discussed private and public/institutional financial opportunities in the €270 Billion Ita ...

| | September | | | --- | --- | --- | | | 30, | March 31, | | | 2024 | 2024 | | | (unaudited) | | | Assets | | | | Cash and cash equivalents | $ 12,708,722 | $ 25,919,945 | | Restricted cash | 8,952,747 | 12,777,148 | | Receivables from broker-dealers and clearing organizations | 12,649,685 | 4,002,982 | | Receivables from customers | 3,923,517 | 3,510,142 | | Loans receivable, net | 13,810,305 | 4,654,635 | | Loan receivable due from a related party, net | 1,657,435 | 1,548,088 | | Securities owned, at fai ...

NEW YORK, Jan. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between July 14, 2023 and July 16, 2024, both dates inclusive (the “Class Period”), of the important February 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Enphase Energy, Inc. (NASDAQ: ENPH) between April 25, 2023 and October 22, 2024, both dates inclusive (the “Class Period”), of the important February 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Enphase common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

TOP RANKED ROSEN LAW FIRM Encourages Paladin Energy Ltd Investors to Inquire About Securities Class Action Investigation - PALAF ...

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sun Communities, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SUI ...

TOP RANKED ROSEN LAW FIRM Encourages Micron Technology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MU ...

NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge’s initial public offering conducted on September 26, 2024 (the “IPO”), of the important March 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased BioAge stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: T ...

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna’s initial public offering conducted on February 8, 2024 (the “IPO”), of the important February 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Kyverna common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...